| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Cyclooxygenase-2 (COX-2). Ocarocoxib is a potent and selective inhibitor of the COX-2 enzyme, with an IC50 of 1.4 uM. By binding to the active site of COX-2, it blocks the conversion of arachidonic acid to prostaglandin H2, the precursor of pro-inflammatory prostaglandins (e.g., PGE2). It exhibits minimal inhibitory activity against COX-1, thereby reducing the risk of gastric ulceration and bleeding complications associated with non-selective NSAIDs.
|
|---|---|
| ln Vitro |
In vitro, ocarocoxib is a potent inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 1.4 uM. It inhibits the COX-2-mediated production of prostaglandins in activated cells, effectively reducing the synthesis of the pro-inflammatory mediator PGE2. Its selectivity for COX-2 over COX-1 is evident in enzyme assays, contributing to a reduced gastrointestinal side effect profile compared to non-selective NSAIDs.
|
| ln Vivo |
No detailed in vivo studies for ocarocoxib are publicly available. As a COX-2 selective inhibitor, it would be expected to produce anti-inflammatory, analgesic, and antipyretic effects in animal models of acute and chronic inflammation (e.g., carrageenan-induced paw edema, adjuvant-induced arthritis). In veterinary medicine, ocarocoxib is used to control pain and inflammation associated with osteoarthritis and postoperative pain in companion animals.
|
| Enzyme Assay |
A COX inhibition assay is performed using purified human recombinant COX-1 and COX-2 enzymes. The enzymes are pre-incubated with serially diluted ocarocoxib (0.1-1000 uM) for 10 minutes at room temperature. Arachidonic acid (100 uM) is then added, and the reaction proceeds for 2 minutes at 37degC. The reaction is stopped with 1 M HCl, and PGE2 production is quantified by ELISA. The IC50 for COX-2 (1.4 uM) and the IC50 for COX-1 are calculated; the selectivity ratio is determined as IC50(COX-1)/IC50(COX-2).
|
| Cell Assay |
For in vitro cellular assays, human whole blood is collected from healthy volunteers. For COX-2 activity, blood is treated with lipopolysaccharide (LPS, 10 ug/mL) to induce COX-2 expression and incubated with serially diluted ocarocoxib (0.1-1000 uM) for 24 hours at 37degC. Plasma is separated, and PGE2 levels are measured by ELISA. For COX-1 activity, blood is allowed to clot at 37degC for 1 hour in the presence of ocarocoxib, and serum TXB2 is measured by ELISA. The IC50 for COX-2 is calculated from the LPS-induced PGE2 inhibition curve.
|
| Animal Protocol |
No published in vivo animal studies are available for ocarocoxib. For research use, a standard rat model of carrageenan-induced paw edema can be used. Male Sprague-Dawley rats receive a subplantar injection of 1% carrageenan into the right hind paw. Ocarocoxib is administered orally at doses of 1-20 mg/kg, 1 hour before carrageenan injection. Paw volume is measured using a plethysmometer at 0, 1, 2, 3, 4, and 6 hours post-injection. Edema inhibition (%) is calculated. Gastric ulcerogenicity is assessed by sacrificing additional animals after 6 hours and examining the stomachs for lesions.
|
| ADME/Pharmacokinetics |
Ocarocoxib has a molecular weight of 328.16 g/mol and a formula of C12H6F6O4. It is a small, lipophilic molecule (LogP ~3.2) with a chromene structure. As a COX-2 selective inhibitor developed for veterinary use, it is orally bioavailable and has a suitable half-life for once-daily dosing in target animal species (e.g., dogs, horses). Detailed PK parameters are not publicly available for research use.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for ocarocoxib are not publicly available. As a selective COX-2 inhibitor, ocarocoxib is expected to have a significantly reduced risk of gastrointestinal ulceration and bleeding compared to non-selective NSAIDs. However, as with other coxibs, potential adverse effects may include renal toxicity, fluid retention, and increased cardiovascular risk at high doses or with long-term use, though these may be less relevant in veterinary applications.
|
| References |
[1]. Carter, Jeffery S, et, al.Substituted benzopyran derivatives for the treatment of inflammation. WO9847890 .
|
| Additional Infomation |
Ocarocoxib is a research-grade compound primarily developed for veterinary medicine as a COX-2 selective NSAID for the treatment of osteoarthritis and postoperative pain in animals. It is not approved for human use. This product is available for laboratory research purposes to study the pharmacology and safety of COX-2 selective inhibition and to evaluate new NSAIDs for veterinary applications.
|
| Molecular Formula |
C12H6O4F6
|
|---|---|
| Molecular Weight |
328.16404
|
| Exact Mass |
328.017
|
| CAS # |
215122-22-8
|
| PubChem CID |
9883880
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.8
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C=C1OC(F)(F)F)C=C(C(O2)C(F)(F)F)C(=O)O
|
| InChi Key |
CSOISVJKLBMNCK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H6F6O4/c13-11(14,15)9-7(10(19)20)4-5-3-6(22-12(16,17)18)1-2-8(5)21-9/h1-4,9H,(H,19,20)
|
| Chemical Name |
6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (304.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0473 mL | 15.2365 mL | 30.4729 mL | |
| 5 mM | 0.6095 mL | 3.0473 mL | 6.0946 mL | |
| 10 mM | 0.3047 mL | 1.5236 mL | 3.0473 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
